MTOR and neoplasm: ,59 This holds significant relevance to uLMS, given the frequent dysregulation of this pathway (1/3 of cases), and some indications that hyper‐activation of the PI3K/mTOR pathway might contribute to resistance to ICB in this specific tumour type.12